{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-024761","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.590566+00:00","generated_at":"2026-06-06T08:23:29.743627+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Royalty Pharma details royalties and funding from Novartis acquisition of MorphoSys at €68/share","bullets":["Royalty Pharma holds 3% royalty on pelabresib (myelofibrosis) and tulmimetostat (EZH2 inhibitor) future sales; NDA submission expected mid-2024.","Tiered mid-single digit royalty on Tremfya (J&J; $3.1B sales FY2023) and 3.3%-4.2% effective royalty on Roche's trontinemab for Alzheimer's.","MorphoSys to make 36 payments totaling ~$660M (2.2x funded $300M) to repay Development Funding Bonds, starting Q4 2024.","Royalty Pharma's 1,337,552 MorphoSys shares valued at ~$100M at proposed Novartis acquisition price.","Royalty Pharma had committed up to $2.025B funding to MorphoSys in July 2021 strategic partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-024761","json":"https://secwatch.observer/filing/0001193125-24-024761.json","markdown":"https://secwatch.observer/filing/0001193125-24-024761.md","text":"https://secwatch.observer/filing/0001193125-24-024761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524024761/0001193125-24-024761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524024761/d105575d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:23:29.743627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}